Abstract
Fanconi-Bickel syndrome (FBS, OMIM 227810) is a rare type of glycogen storage disease (GSD). It is caused by homozygous or compound heterozygous mutations within GLUT2, the gene encoding the most important facilitative glucose transporter in hepatocytes, pancreatic b-cells, enterocytes, and renal tubular cells. To date, 112 patients have been reported in the literature. Most patients have the typical combination of clinical symptoms: hepatomegaly secondary to glycogen accumulation, glucose and galactose intolerance, fasting hypoglycemia, a characteristic tubular nephropathy, and severely stunted growth. In 63 patients, mutation analysis has revealed a total of 34 different GLUT2 mutations with none of them being particularly frequent. No specific therapy is available for FBS patients. Symptomatic treatment is directed towards a stabilization of glucose homeostasis and compensation for renal losses of various solutes. In addition to the clinical and molecular genetic aspects of FBS, this review discusses the pathophysiology of the disease and compares it to recent findings in GLUT2 deficient transgenic animals. An overview is also provided on recently discovered members of the rapidly growing family of facilitative glucose transporters, which are novel candidates for congenital disorders of carbohydrate metabolism.
Keywords: fanconi-bickel syndrome, facilitative glucose transport, glycogen storage disease, glucose transporter2 (glut2)
Current Molecular Medicine
Title: Fanconi-Bickel Syndrome - A Congenital Defect of Facilitative Glucose Transport
Volume: 2 Issue: 2
Author(s): R. Santer, B. Steinmann and J. Schaub
Affiliation:
Keywords: fanconi-bickel syndrome, facilitative glucose transport, glycogen storage disease, glucose transporter2 (glut2)
Abstract: Fanconi-Bickel syndrome (FBS, OMIM 227810) is a rare type of glycogen storage disease (GSD). It is caused by homozygous or compound heterozygous mutations within GLUT2, the gene encoding the most important facilitative glucose transporter in hepatocytes, pancreatic b-cells, enterocytes, and renal tubular cells. To date, 112 patients have been reported in the literature. Most patients have the typical combination of clinical symptoms: hepatomegaly secondary to glycogen accumulation, glucose and galactose intolerance, fasting hypoglycemia, a characteristic tubular nephropathy, and severely stunted growth. In 63 patients, mutation analysis has revealed a total of 34 different GLUT2 mutations with none of them being particularly frequent. No specific therapy is available for FBS patients. Symptomatic treatment is directed towards a stabilization of glucose homeostasis and compensation for renal losses of various solutes. In addition to the clinical and molecular genetic aspects of FBS, this review discusses the pathophysiology of the disease and compares it to recent findings in GLUT2 deficient transgenic animals. An overview is also provided on recently discovered members of the rapidly growing family of facilitative glucose transporters, which are novel candidates for congenital disorders of carbohydrate metabolism.
Export Options
About this article
Cite this article as:
Santer R., Steinmann B. and Schaub J., Fanconi-Bickel Syndrome - A Congenital Defect of Facilitative Glucose Transport, Current Molecular Medicine 2002; 2 (2) . https://dx.doi.org/10.2174/1566524024605743
| DOI https://dx.doi.org/10.2174/1566524024605743 |
Print ISSN 1566-5240 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
Call for Papers in Thematic Issues
From Molecular Mechanisms to Therapeutic Frontiers: The Versatile Roles of Chaperones in Medicine
Chaperones play critical roles in maintaining proteostasis by preventing protein misfolding and aggregation, which constitute central processes to the pathogenesis of numerous diseases such as neurodegeneration, cancer, and inflammatory disorders. This thematic issue will delve into the molecular mechanisms of chaperone function, their involvement in disease progression, and their potential ...read more
Metabolic Reprogramming and Molecular Pharmacology: Innovations in Drug Discovery and Therapeutic Targeting
Metabolic reprogramming is a hallmark of numerous diseases, including cancer, metabolic disorders, and neurodegeneration. Understanding the intricate cell signaling pathways, transduction pathways, and omics-based data is important for the development of novel pharmacological interventions. This special issue of Current Molecular Medicine will be devoted to the current advances in drug ...read more
Molecular and Cellular Mechanisms in Vertigo / Vestibular Disorders
Vertigo and vestibular diseases are common among middle-aged and older adults, significantly increasing the risk of falls and leading to injuries and disabilities. Despite their prevalence, therapeutic advancements are hindered by a limited understanding of the underlying molecular and cellular mechanisms. This Special Issue is dedicated to bridging this gap ...read more
Related Journals
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Herbal Drugs for Diabetic Treatment: An Updated Review of Patents
Recent Patents on Anti-Infective Drug Discovery Iodine Deficiency and Iodine Prophylaxis in Pregnancy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Role of Chymase in Preeclampsia
Current Vascular Pharmacology miRNAs in Insulin Resistance and Diabetes-Associated Pancreatic Cancer: The ‘Minute and Miracle’ Molecule Moving as a Monitor in the ‘Genomic Galaxy’
Current Drug Targets Drug Transport Across the Placenta
Current Pharmaceutical Biotechnology Circulating and Vascular Bioactive Factors During Hypertension in Pregnancy
Current Bioactive Compounds Stromal Cell-Derived Factor (SDF) 2 and the Endoplasmic Reticulum Stress Response of Trophoblast Cells in Gestational Diabetes Mellitus and <i>In vitro</i> Hyperglycaemic Condition
Current Vascular Pharmacology Current Concepts and Controversies in the Use of Antenatal Corticosteroid Therapy for Prevention of Neonatal Morbidities
Current Women`s Health Reviews Oxytocin in the Heart Regeneration
Recent Patents on Cardiovascular Drug Discovery Age-Related Changes and Effects of Mild Hypothermia on Carotid Artery Reactivity in Newborn Rats
CNS & Neurological Disorders - Drug Targets Empowering Translational Research in Fetal Growth Restriction: Sheep and Swine Animal Models
Current Pharmaceutical Biotechnology Aptamer-based Biosensors: Promising Sensing Technology for Diabetes Diagnosis in Biological Fluids
Current Medicinal Chemistry Insulin Resistance and Diabetes Mellitus in Patients with Systemic Lupus Erythematosus
Endocrine, Metabolic & Immune Disorders - Drug Targets <i>In vitro</i> and <i>In vivo</i> Evaluation of the Antidiabetic Activity of <i>Solidago virgaurea</i> Extracts
Current Bioactive Compounds GSK3 at the Edge: Regulation of Developmental Specification and Cell Polarization
Current Drug Targets Depression Under the Perspective of Oxytocin
Central Nervous System Agents in Medicinal Chemistry Hypertension and Diabetes: Emphasis on the Renin – Angiotensin System and Insulin Resistance
Current Hypertension Reviews Future of Cardiac Pacemaker – an Update of Biological Pacemaker Patents
Recent Patents on Biomedical Engineering (Discontinued) Perinatal Exposure to Bisphenol A and Developmental Programming of the Cardiovascular Changes in the Offspring
Current Medicinal Chemistry Functions of S100 Proteins
Current Molecular Medicine





